The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...

Eli Lilly is strengthening its position ... The therapy is part of Lilly’s broader push into gene therapy. In April 2025, Lilly inked a deal worth $1.4bn with Sangamo Therapeutics to develop ...

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly and Company (NYSE:LLY) also signed a $1.4 billion deal with Sangamo Therapeutics for CNS gene therapy in April 2025. Industry focus on genetic hearing loss treatments is growing ...

Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics.

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.